MT CSI Advisory Memorandum of 2022-04-14 (2023 Form, Rate, and Network Adequacy Filing Requirements Including Qu)
2023 Form, Rate, and Network Adequacy Filing Requirements Including Qualified Health Plan Certification
COMMISSIONER OF SECURITIES AND INSURANCE
Troy DO'\,vning
Commissioner
Office of the
Montana State Auditor
ADVISORY MEMORANDUM
To:
ALL INTERESTED PERSONS
From:
TROY DOWNING
Commissioner of Securities and Insuranc , Office of the Mo
Date:
April 14, 2022
2023 Form, Rate, & Network Adequacy Filing Requirements Including Qualified
Health Plan Certification
The Office of the Montana State Auditor, Commissioner of Securities and Insurance (CSI), will
continue to perform the plan management functions required for issuers choosing to participate
in the Federally Facilitated Marketplace (FFM) in 2023.
This Memorandum provides instructions for filing both on-exchange and off-exchange health
plans. Center for Medicare & Medicaid Services (CMS) has issued a 2023 Draft Notice of Benefit
Payment Parameters (Proposed Rule), which proposes changes to the payment parameters as
described below in the "Items of Note for 2023." (See www.federalregister.gov/documents/
2022/01/05/2021-28317/patient-protection-and-affordable-care-act-hhs-notice-of-benefit
and-payment-parameters-for-2023.) This Memorandum's description of the form, rate, &
network adequacy filing requirements does not include the changes proposed in the Proposed
Rule. To the extent that the finalized 2023 Notice of Benefit and Payment Parameters changes
the form, rate, & network adequacy filing requirements described herein, CSI will issue an
addendum as needed.
TABLE OF CONTENTS:
Introduction......................................................................................................
1
Filing Requirement Due Dates.........................................................................
2
Items of Note for 2023 .....................................................................................
2
Form Filings ......................................................................................................
4
Prescription Drug Coverage ........................ ......... .............. ... ....... ... .....
5
Product Withdrawals .. . . . . . . . ..... . . . .. . .. .. . . .. . .. . . . . ... .. . . . . . . . .. . .. . . . . . . . . . .. . . . . . . . . . . . . .
5
Healthcare Co-Ops, Student Health Plans, and Multi-State Plans .....
5
Stand-Alone Dental Plans ....................................................................
6
Large Employer Group Insurance .... ....................................................
6
Filing Fee .... ................... .. ......... .... ......... ............... ........... .......... .. .........
6
Medical Rate Filings . ............ ......... .......... ......... ........... ............. ......... .. ..... ........
6
Guidance in CCIIO/CMS 2023 Letter to Issuers..............................................
9
Network Adequacy ............................................................................................
10
Technical Assistance for Issuers & Consumer Complaint Handling .. . .... .... .. ..
11
Contact Information ............................... ......... ............................ ........ ...... ........
11
April 14, 2022
Page 2
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
Due to federal requirements, the timeline for filing plans and rates for 2023 is the same for both
qualified health issuers (QHP issuers) and health issuers with no QHPs (non-QHP issuers).
Filing Requirements for Montana
Due Date
Binder, Form, & Network Info Due
May 20, 2022
Rate Filings Due
May 20-June 6, 2022
Initial Rate Transfer to CMS
June 15, 2022
Final day for Issuers to make changes to Binder, Form, and Rates
August 5,2022
CMS Binder Final Deadline
August 17, 2022
ITEMS OF NOTE FOR 2023
1)
System for Electronic Rate and Form Filing (SERFF Required). All filings must
be submitted through the System for Electronic Rate and Form Filing (SERFF). SERFF
has made updates to the Unified Rate Review (URR) transfer process. Going forward, all
Unified Rate Review Template (URRT) submissions should be completed within SERFF
and not directly in the Health Insurance Oversight System (HIOS) URR module. All new
filings need to be submitted using the new SERFF to URR Transfer Process. This is done
by using the new URRT Tab in SERFF. If an issuer enters their rate submission
incorrectly through HIOS instead of SERFF, CMS will be deactivating that submission
and notifying the issuer and the state that it must be entered through the SERFF
Transfer Process.
2) Risk Adjustment Transfer Elements Extract (RATEE) File. As with previous
years, the CSI will again be requesting that issuers provide their final RATEE file. The
CSI will notify issuers via email with further details.
3) URRT. The updated URRT and corresponding URR instructions have been released by
CMS and are required for 2023 rate filings. Please see:
https://www.qhpcertification.cms.gov/s/Unified%20Rate%20Review
4) Silver Loading Guidance Clarified. Cost-Sharing Reduction (CSR) plan designs are
required by federal law, however, that additional cost is not required be paid with federal
funds. If the unfunded cost is distributed to all plans, the CSI agrees the load is unfairly
forced upon the insured members who are not eligible for the CSR plans through
increased premiums for the non-CSR eligible plan designs. The Commissioner prioritizes
consumer protection. Charging unfairly high rates on the non-CSR-eligible plan designs
conflicts with the responsibility to ensure that rates are neither excessive nor unfairly
discriminatory. As such, the Commissioner expects that issuers will develop rates for
Affordable Care Act (ACA) plans that distribute the cost of CSRs only to CSR-eligible
plans. Since CSR eligibility requires that a policy be exchange-sold, issuers may consider
distributing the burden only to plans that are available on the exchange. Note, however,
that all plans sold on the exchange must be sold off-exchange at the same premium rate.
April 14, 2022
Page 3
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
5) New Actuarial Value (AV) Calculator. CMS has released a new AV Calculator and
methodology for 2023 that can be found here:
https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/Draft-
2023-AV-Calculator-Methodology.pdf
https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/Draft-
2023-AV-Calculator.xlsm
6) Reinsurance Program Rate Requirement. Issuers must include in their filing a
report detailing premium amounts with and without taking the reinsurance program
into consideration. See Medical Rate Filings Section for more details for 2023.
7) Defrayal of State Mandated benefits. The State of Montana is required to defray
benefits from HB 291 that added a state mandate requiring coverage for children with
hearing loss. The issuers will be required to submit the relevant claims incurred and paid
in 2022 to the CSI for review. The CSI will provide additional guidance to the issuers on
the process to submit the claims. This applies to issuers in both the individual and small
employer market.
For the 2023 plan year the rate filing will need to reflect the defrayal cost estimated as
they did for the 2022 plan year. The Actuarial Memorandum should state the amount the
issuer anticipates the state will defray and issuers should follow instructions in URRT on
how to annotate benefits in addition to essential health benefits (EHB). This applies to
issuers in both individual and small employer market.
8) CMS Proposed Rule on Discrimination of Benefit Design. Currently, CMS
proposed rule provide that an issuer does not provide a EHB “if its benefit design, or the
implementation of its benefit design, discriminates based on an individual’s age,
expected length of life, present or predicted disability, degree of medical dependency,
quality of life, or other health conditions.” 45 CFR § 156.125 (“EHB nondiscrimination
provision”). With the Draft 2023 NBPP, CMS has proposed to add sexual orientation
and gender identity to the list of protected classes in the EHB nondiscrimination
provision, as well as other nondiscrimination requirements, including, in part,
regulations related to guaranteed availability of coverage under § 147.104; and Exchange
standards under § 155.120; and standards of conduct for agents, brokers and webbrokers under § 155.220.
In addition, CMS identified a number of presumptively discriminatory benefit designs
that will not be considered EHBs under § 156.125, including but not limited to
limitations on coverage for hearing aids for children 18 and under, routine foot care for
diabetics or any other health condition, autism spectrum disorder for children 18 and
under, limitation of an EHB for gender-affirming therapy, and adverse tiering related to
access to prescription drugs for chronic health conditions. The CSI interprets that the
proposed rule allows for issuers to provide justification on why a benefit design may not
be discriminatory.
9) Prescription Drug Tearing. CMS noted that adverse tiering of prescription drugs has
the potential to be in conflict with the EHB nondiscriminatory provision in § 156.125.
According to CMS, placing all drugs for a high-cost chronic condition on the highest
April 14, 2022
Page 4
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
formulary tier is a presumed discriminatory design, even when those drugs are costly.
Plans and issuers should expect to demonstrate that neutral principles were used
assigning tiers to such drugs and that those principles were consistently applied across
types of drugs.
10) Standardized QHP Options. CMS proposes to require issuers of QHPs in FFM to
offer standardized QHP options at every product network type, metal level, and
throughout every service area that a non-standardized option is offered. For example, if
an FFMF issuer offers a non-standardized gold Health Maintenance Organization
(HMO) QHP in a particular service area, that same issuer must also offer a standardized
gold HMO QHP throughout that same service area.
11) Changes to Network Adequacy. CMS proposes to evaluate QHPs for compliance
with network adequacy standards based on time and distance standards and
appointment wait time standards. In addition, for plans that use tiered networks, to
count toward the issuer’s satisfaction of network adequacy standards, providers must be
contracted within the network tier that results in the lowest cost-sharing obligation.
CMS is collecting from QHPs information on whether providers participating in their
network offer telehealth services. For plan year (PY) 2023, this data is for informational
purposes only. This does not mean that telehealth services can be counted in place of inperson service access for the purpose of satisfying network adequacy standards. CMS is
increasing the ECP (Essential Community Providers) threshold from 20% to 35%, and
ECPs have to be contracted within the network tier that results in the lowest cost-sharing
obligation for the respective plan’s enrollees to count toward the issuer’s satisfaction of
each element of the ECP standard.
FORM FILINGS
All major-medical health issuers that wish to issue or renew small employer group, individual
health insurance coverage, or standalone dental plans must file with the CSI their network
information, forms, and binders – including all required documents for policies, certificates or
membership contracts and their plan binders containing all required templates for coverage that
will be issued on or after January 1, 2023, no later than 5:00 PM MDT on May 20, 2022. The
opportunity for all required filing submissions will open as soon as SERFF allows Binder
submissions. Late filings will not be accepted.
If a policy form to be used in 2023 has no changes from the approved form for 2022, the issuer
may file an attestation certifying that there are no changes in the form. However, any changes to
cost-sharing will require a new filing for the Summary of Benefits (SBC), Outline of Coverage
(OOC), and Schedule of Benefits (SOB) documents. Note: new templates must be filed
every year, even if there are no changes in the policy language.
All SBCs and OOCs must be filed at the same time as the policy forms. See CSI’s bulletin on
SBC’s and OOC’s, entitled “Federal and State Consumer Disclosures”, dated July 6, 2012 here:
https://csimt.gov/wp-content/uploads/07062012_FedStateConsumerDisclosures.pdf. All
required corrections to forms and templates must be made by the issuer on a continuous basis.
The CSI will not use “correction windows.” Center Consumer Information and Insurance
Oversight (CCIIO) will send all substantive corrections to the CSI BEFORE sending those
requested corrections to the health issuer. Please do not make corrections without first receiving
approval from the CSI.
April 14, 2022
Page 5
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
Corrections to all rate, network information, form, and binder filings must be
finalized by 5:00 PM MDT on August 5, 2022. No exceptions will be permitted.
Prescription Drug Coverage
QHP issuers must comply with the final PY 2023 EHB Crosswalk in setting formulary design.
The effective Crosswalk was updated in 2022, to contain 8359 Clinical Drug Components
(RXCUIs), representing 1531 chemically distinct drugs, 47 categories and 156 classes for a
combination of 169 unique category/class combinations. Additional information is available
here:
https://www.qhpcertification.cms.gov/s/Review%20Tools
An issuer’s formulary drug list must be displayed on the issuer’s website and updated regularly
as required by state and federal laws. Formulary lists will be reviewed to ensure assignment of
drugs to tiers does not discriminate, as defined in Section 1557 of the ACA.
Issuers may not require that prescription be obtained through a mail order pharmacy, as
members must have access to retail pharmacy services.
Issuers must provide for a drug formulary exception process that complies with the federal
regulation (see 45 CFR 156.122) and provides for a decision within 72 hours, or 24 hours if an
expedited exception request is received. In addition, issuers must follow state law (see Mont.
Code Ann. Title 33, Chapter 32) regarding internal and external appeals if the member requests
an appeal of an adverse benefit determination on a drug claim.
CMS noted that adverse tiering of prescription drugs has the potential to be in conflict with the
EHB nondiscriminatory provision in § 156.125. In order not to discriminate under § 156.125, the
issuer’s EHB prescription drug benefit design must be clinically based. According to CMS,
placing all drugs for a high-cost chronic condition on the highest formulary tier is a presumed
discriminatory design, even when those drugs are costly. Plans and issuers should expect to
demonstrate that neutral principles were used when assigning tiers to such drugs and that those
principles were consistently applied across types of drugs.
Product Withdrawals
If an issuer is discontinuing any products in the individual, small group or large group markets,
the issuer must provide the CSI with a list of withdrawn products and the number of members
affected by that withdrawal. In addition, the issuer must specify how each of those plans will be
“mapped” to a 2023 plan when “auto-renewal” occurs. The CSI will not allow mapping to a lower
metal tier without the express written permission of the Commissioner. The mapping
information submitted must include a detailed plan comparison between the old plan and the
new plan. The detailed plan comparison must be included in the renewal notice to the insured.
Healthcare Co-Ops, Student Health Plans, and Multi-State Plans
While healthcare co-op plans are “deemed” certified as described in the CCIIO/CMS 2023 Letter
to Issuers, the CSI will review co-op health plan forms in the same manner as all other health
issuers’ plan forms are reviewed. All timelines and instructions contained in this Advisory
Memorandum apply equally to healthcare co-ops.
April 14, 2022
Page 6
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
Similarly, the CSI will review multi-state plans (MSPs) under contract with the Office of
Personnel Management according to the same instructions and timelines outlined in this
Advisory Memorandum. MSP issuers are treated as a separate issuer.
Pursuant to federal law, student health plan forms and rates must be filed and reviewed as
individual health insurance products. The only distinctions from the individual market allowed
are those identified in federal regulations that apply specifically to student health plans. Student
health plans must be filed and reviewed by the CSI at least 60 days before they are offered for
sale. The student health plan forms and rate filings do not need to follow the URR filing
requirements; therefore, a binder filing is no longer required. The submission of forms and rates
with supporting documentation are the only documents required to be submitted in SERFF. For
more detailed instructions, please contact the CSI.
Stand-Alone Dental Plans
Qualified Stand-alone Dental Plans (SADPs) must file their forms, plan binders and network
lists according to the same timelines and instructions that apply to all QHP issuers. Rates should
be filed in conjunction with the form and binder filings. Montana’s PPO network adequacy laws
apply to dental plans. The benefits template will be modified for dental plans as described in the
CCIIO/CMS 2023 Letter to Issuers. Each SADPs issuer must specify whether the rates contained
in the templates are guaranteed to consumers or will be subject to underwriting.
SADP forms, rates and binders must be filed separately from QHP filings. Dental rates may use
geographic rating factors that differ from those used for the medical rates, however, the
geographic rating areas used must be the same as those identified for health plans. Dental
binders/filings should include all SADPs sold on and off the exchange.
Large Employer Group Insurance
Large employer group insurance issuers must follow the instructions regarding network lists
required to be filed annually as well as instructions regarding product withdrawal. Policy forms
must be updated as needed to comply with state and federal regulations.
Filing Fee
If you are a health service corporation required to pay a filing fee, please make sure to submit
the filing fee for each binder.
MEDICAL RATE FILINGS
Rate filings will only be accepted from May 20-June 6, 2022 and are due by 5:00
PM MDT June 6, 2022. Proposed rate increases will be published on or before
CMS’ August 17th deadline.
All issuers operating in the Individual and Small Group major medical market
must submit the federal Rate Data Template (RDT) (filed in the plan binder) and
the URRT, even if issuers do not intend to sell on the FFM.
Reinsurance Program Rate Requirement: Montana has received a Section 1332 State
Innovation Waiver allowing the state to implement a reinsurance program (Program) in the
April 14, 2022
Page 7
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
individual market. For all years that the Program is in place (January 1, 2020 through December
31, 2024), and for federal pass-through funding calculation purposes:
•
Issuers must include in their filing a report detailing premium amounts with and without
taking the reinsurance program into consideration.
•
Issuers must submit the “without reinsurance” RDT under a user-created Rate/Rule
Schedule Item in the rate filing (the "with reinsurance” RDT will continue to be
submitted under the binder filing as required by CMS).
•
A separate “without reinsurance” URRT must be submitted under a user-created
component on the Supporting Documents tab in the SERFF rate filing. The “with
reinsurance” URRT must be submitted under the URRT tab in the SERFF rate filing.
A rate filing that contains the URRT and is separate from the form filing and the plan binder
must be filed. Do not duplicate templates submitted in the plan binder (RDT) in the rate filing.
Part I (Unified Rate Review Template), Part II (consumer justification narrative) and Part III
(actuarial memorandum) of the Rate Filing Justification and all supporting documentation for
the rates should be submitted in a separate SERFF rate filing. These files are not part of the plan
binder.
There is no required format for Part II. However, for consistency, the document should adhere
to the URR instructions including all sections in the order listed (scope and range of the rate
increase, financial experience of the product, changes in medical service costs, changes in
benefits, and administrative costs and anticipated margins). If there are additional material
components of the rate change that do not fit into any of the above sections, please add sections
at the end to address them.
Part II serves two purposes – it will be posted in PDF format to the CSI’s website regardless of
average or plan-level rate impact (as noted elsewhere in this document), and it will also be
posted in PDF in HIOS if any renewing plan within a product has a rate increase of 15% or more.
Although there are not specific CSI instructions for Part II, since the PDF is posted to the CSI
website, Part II should discuss not only the HIOS-required change derived by the URRT, but
also the actuary’s best estimate of the impact of the rate change on the current insured members
as reported in SERFF (note – Part III’s discussion of rate impact should also address both
perspectives). Part II should include a header containing the following identifying information:
•
Title – Part II Justification for Proposed Rate Increase;
•
Issuers name;
•
Market segment (individual or small group); and
•
Rate effective date.
Additional instructions related to rate filings:
•
Geographic rating factor support must include documentation regarding how
utilization was removed from the development of the proposed rating factors
April 14, 2022
Page 8
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
•
Parts I, II and III of the Rate Filing Justification for ALL individual and small
employer group health plans must be completed and submitted in SERFF.
•
All filings need to be submitted using the new SERFF to URR Transfer Process. This
is done by using the new URRT Tab in SERFF.
•
The Company Rate Information and the Rate Review Detail on the Rate/Rule
Schedule tab in SERFF must be completed for all filings. The values for rate impact
generally should agree with those reported in the URR Parts II and III. Although no
determination method of the rate impact is mandated, the CSI requires that support
be provided in the rate filing. Please submit this support in SERFF separately from
the URR components.
•
The URRT, Part II Consumer Justification and Part III Actuarial Memorandum are
required to be included in SERFF under the URRT tab in the rate filing. Please do
not include them as attachments as notes to reviewers, under the Rate/Rule
Schedule items tab or under the Supporting Documents tab.
•
Tobacco use rating is not allowed for anyone under the age of 21. This applies to
policies sold both on and off the exchange.
•
Individual Market health plan rates, both on and off the exchange, must be
guaranteed for the calendar year beginning January 1, 2023. No interim rate
revisions will be permitted.
•
Rates for the Small Group Market, both on and off the exchange, must be filed for the
entire 2023 calendar year. The initial rates for 2023 may be submitted with quarterly
trend factors for the entire year. Subsequent quarterly rate revisions will be accepted
but as outlined in the URR instructions, must be submitted at least 105 days prior to
the effective date of the rate change and finalized at least 45 days prior to the
effective date.
•
Small group rates are allowed to be composite billed in Montana. Issuers must
indicate this for each plan on the Benefit Package tabs in the Plan and Benefit
template. CMS has given the CSI authorization to require accurate responses on the
Plan and Benefit template. An indication of to which plans composite billing applies
should also be included in Part III under the Effective Rate Review Information
section. When quoting for dual options, the composite rates for each plan should be
calculated using the entire census.
•
Rates entered into the RDT should have no more than 2 decimal places in order to
avoid validation errors later in the review.
•
As in past years, the components of the AV Pricing Values, as described in 45 CFR
156.80(d)(2), must be documented, and supported in the filing. No template will be
provided for this information; it is recommended that these components be
summarized in a table in Part III.
•
Based on the CMS instructions for Parts I & III, there are two distinct
subcomponents to the AV and cost-sharing design component described in
§156.80(d)(2)(i) – cost-sharing design and utilization differences as a result of the
April 14, 2022
Page 9
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
design. Attention will be paid to the justification for the assumed utilization
differences.
•
The Market-Wide Adjusted Index Rate (MAIR) must be fully supported in the Part
III and equal to that reported on the URRT.
•
Plan Adjusted Index Rate (PAIR) components need to be supported in Part III.
Issuers must report Administrative Expenses, Taxes and Fees, and Profit and Risk
Load and detailed support must be provided in Part III. Additionally, issuers are
required to provide an explanation of how these modifiers are developed and applied
to the MAIR to derive the PAIR.
•
The CSI requires documentation of the MLR development, including support for
each component (including plan-level variation), with the specific requirement of
reconciliation of the MLR Exchange User Fees with that on the URRT.
•
As noted in the CMS Part III instructions, the actuary may qualify his or her opinion
to state that Part I does not demonstrate the process used to develop the rates, but
this does not negate the requirement that the assumptions used to develop the rates
be accurately captured in Part I and thoroughly documented and supported in Part
III.
If an issuer wishes to identify any part of the rate filing as confidential, it must first be identified
as a “trade secret.” Do not mark the entire filing as a “trade secret.” Reasons for a trade secret
determination must be specific for each item of information in the rate filing. Each item that
properly deserves trade secret status must be clearly identified and accompanied by an affidavit
from an authorized company representative identifying specific reasons under Montana law that
legally justifies the company’s claim for trade secret designation for that particular information.
The Part II justification for a filed rate increase must be published pursuant to federal law and
cannot be designated a trade secret. The Commissioner or his designee will review and make the
ultimate determination as to trade secret status. After the rate review process is complete, all
parts of the rate filing will be treated as public unless trade secret status has been granted by the
Commissioner. Please contact the CSI for more detailed instructions if you have questions.
Rate justifications, as required by applicable federal regulations and contained in Part II of the
URR, must be submitted with the initial rate filing and for all subsequent rate increases, no
matter how large or small the increase. The Part II rate justification is the consumer- friendly
explanation/justification for the rate. Rate justifications will be posted on the CSI’s website
immediately after they are received for all health plans sold in Montana, both on and off the
exchange.
GUIDANCE IN THE CCIIO/CMS 2023 LETTER TO ISSUERS
All health issuers should carefully review the CCIIO/CMS 2023 Letter to Issuers in the
Federally-facilitated Exchanges that is posted on the CMS website; please see
https://www.cms.gov/files/document/2023-draft-letter-issuers-508.pdf.
April 14, 2022
Page 10
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
NETWORK ADEQUACY
To assess compliance with state and federal network adequacy laws for Preferred Provider
Organization (PPO) and “PPO-type” health plans offered in 2023, health, vision, and dental
issuers (including non-QHP issuers), must provide the CSI with a completed healthcare provider
template for each health, vision, and dental plan offered for sale in Montana. If an issuer uses a
different network for different health plans, all networks must be properly identified and
submitted separately.
All networks must be resubmitted each year by all health, dental, and vision
issuers, even if there are no other changes to the policy form.
Plans defined under Mont. Code Ann. Title 33, Chapter 31 as Health Maintenance Organizations
(HMOs) must seek a network adequacy determination through the Montana Department of
Public Health and Human Services (DPHHS) pursuant to Title 33, Chapter 36.
HMO issuers must submit to the CSI the network adequacy determinations received from
DPHHS. However, due to federal ACA requirements and QHP certification requirements,
issuers who are filing HMO health plans must also submit the relevant CSI network adequacy
templates to the CSI. As the plan manager, the CSI must review the adequacy of the network
pursuant to federal standards.
The CSI’s healthcare provider template submitted must report the following provider types:
•
advanced practice registered nurses,
•
chiropractors,
•
licensed addiction counselors,
•
licensed clinical professional counselors,
•
licensed clinical social workers,
•
licensed marriage and family therapists, naturopaths, optometrist, physical
therapists, physician assistants, physicians, and psychologists.
The CSI uses a list of facilities to determine network adequacy for hospitals and other types of
facilities. This list includes hospitals, critical access hospitals, residential treatment centers,
surgical centers and chemical dependency treatment centers. The CSI’s facilities template must
be submitted for each network.
Excel workbook templates, which include instructions detailing the required information and
format for submitting the in-network healthcare providers, facilities, pharmacies, and essential
community providers, can be found on the CSI’s website at www.csimt.gov and in the State filing
instructions on SERFF.
Stand-alone dental and vision plans do not need to complete and submit a facility template or
essential ECP template at this time; only the CSI healthcare provider template must be
submitted.
April 14, 2022
Page 11
840 Helena Avenue, Helena, Montana 59601
(main fax) 406.444.3497 I (securities fax) 406.444.5558
(policyholder services fax) 406.444.1980 I (legal fax) 406.444.3499
(phone) 800.332.6148 or 406.444.2040 I (email) csi@mt.gov I (web) www.csimt.gov
If an issuer requires use of “preferred pharmacies” or offers better pricing for prescription drugs
obtained at a preferred pharmacy, the CSI’s pharmacy template must be completed and
submitted.
Once finalized, the master list of healthcare providers used by the CSI to review healthcare
provider networks for 2023 will be available upon request.
All QHP issuers must include ECPs in their networks. ECPs are defined in federal law as those
providers that serve low-income and medically underserved individuals. ECPs must be
contracted within the network tier that results in the lowest cost-sharing obligation for the
respective plan’s enrollees to count toward the issuer’s satisfaction of each element of the ECP
standard. Note: the list of ECPs published by CMS for Montana maybe incomplete. The federal
network adequacy standard requires only 35 percent of all ECPs to be “in network”; however,
that percentage is not adequate to meet the requirements of Montana law. QHP issuers should
strive to meet a standard that includes at least 80 percent of all ECPs on the CSI’s ECP template.
If a health plan is unable to meet that standard, the CSI will review the ECP network and make a
determination as to adequacy based on the Administrative Rules of Montana 6.6.5901, et seq.
If a QHP issuer does not include all Indian health care providers in its networks, it must submit
proof, in the form of an attestation, that a provider contract was offered to and refused by the
Indian provider. The attestation must outline its attempts to contract with the Indian providers.
Rate, form and template reviews cannot be completed until the adequacy of the
network is determined and approved by the Commissioner. Additionally, QHP
issuers must also complete and submit the required CMS network and ECP
templates.
TECHNICAL ASSISTANCE FOR ISSUERS & CONSUMER COMPLAINT HANDLING
The CSI will continue to provide technical assistance to issuers throughout the form
approval/QHP certification recommendation process. All consumer complaints regarding
issuers, including QHP issuers, will be handled by the CSI. Consumer complaints regarding
issuers received by the FFM through its toll-free phone number, the FFM website, or in any
other manner, will be forwarded to the CSI for resolution. The CSI will track complaints
concerning QHP issuers and forward to the FFM when requested.
CONTACT INFORMATION
If you have questions, please contact the following people:
Forms and Binders: Karen Beyl (kbeyl@mt.gov )
Network Adequacy: David Dachs (ddachs@mt.gov )
Rates: Ashley Perez (aperez@mt.gov)
This advisory memorandum is informational only and does not enlarge, delimit,
or otherwise modify any requirements of applicable law or in any way limit the
authority of CSI under applicable law. CSI encourages interested persons to
consult with independent legal counsel for guidance on the application of law to
any particular circumstances.